$RARE

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Its approved products include Crysvita for X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii for MPS VII, Dojolvi for long-chain fatty acid oxidation disorders, and Evkeeza for homozygous familial hypercholesterolemia. Its clinical candidates include biologics, small molecules, AAV gene therapies and nucleic acid medicines for conditions such as Sanfilippo syndrome type A, glycogen storage disease type Ia, Angelman syndrome and Wilson disease. Ultragenyx earns money through product sales and commercial arrangements, including revenue shares, royalties and collaborations with partners. It sells directly in some territories and works with partners or third-party distributors in others. Its commercial organization serves markets across North America, Europe, Latin America, Türkiye, Asia and select international markets. Ultragenyx is headquartered in Novato, California.

0
1
0

No SEC Form 4 filings for $RARE in the last 30 days.

See all $RARE insider activity →
Med

Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches

Ultragenyx Pharmaceutical (RARE) aims for profitability by 2027, driven by gene therapy launches and potential next-gen versions of Crysvita. CEO Kakkis reported positive early interest in FAYUVI and GENGLYCOS, with launch data expected in January. The company is also discussing setrusumab's next steps with the FDA after a missed endpoint in the ORBIT study and is studying DTX301 for ornithine transcarbamylase deficiency.

Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split

Dr. Reddy's (RDY) secured Brazil approval for generic semaglutide and tentative FDA approval for an HIV prevention shot. Lupin (LUPIN.NS) and Sun Pharma (SUNPHARMA.NS) received FDA approvals for generic Firdapse and Ilumya. Agios (AGIO) and Ultragenyx (RARE) announced significant job cuts. CVS (CVS) plans to split into two publicly traded companies. Teva (TEVA) expanded its biosimilars portfolio through a deal with Samsung Bioepis.

Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down

Eli Lilly partners with Hims & Hers to offer obesity drugs Zepbound and Foundayo on its platform. Alnylam's Chief Commercial Officer Tolga Tanguler is stepping down. Boehringer Ingelheim forms a $7B cancer drug alliance with Sino Biopharmaceutical. Servier's experimental drug sevasemten fails a mid-stage trial. Ultragenyx cuts 20% of workforce and halts studies. ANI Pharmaceuticals offers to acquire Egetis Therapeutics for $560M.

RARE sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning RARE (Ultragenyx Pharmaceutical Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent RARE coverage spans financial news and regulation.

What's driving RARE

AlphAI scores every news story that mentions RARE with an AI model for sentiment and relevance, and aggregates insider trades from Ultragenyx Pharmaceutical Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RARE

Score

Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches

Ultragenyx Pharmaceutical (RARE) aims for profitability by 2027, driven by gene therapy launches and potential next-gen versions of Crysvita. CEO Kakkis reported positive early interest in FAYUVI and GENGLYCOS, with launch data expected in January. The company is also discussing setrusumab's next steps with the FDA after a missed endpoint in the ORBIT study and is studying DTX301 for ornithine transcarbamylase deficiency.

Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split

Dr. Reddy's (RDY) secured Brazil approval for generic semaglutide and tentative FDA approval for an HIV prevention shot. Lupin (LUPIN.NS) and Sun Pharma (SUNPHARMA.NS) received FDA approvals for generic Firdapse and Ilumya. Agios (AGIO) and Ultragenyx (RARE) announced significant job cuts. CVS (CVS) plans to split into two publicly traded companies. Teva (TEVA) expanded its biosimilars portfolio through a deal with Samsung Bioepis.

Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down

Eli Lilly partners with Hims & Hers to offer obesity drugs Zepbound and Foundayo on its platform. Alnylam's Chief Commercial Officer Tolga Tanguler is stepping down. Boehringer Ingelheim forms a $7B cancer drug alliance with Sino Biopharmaceutical. Servier's experimental drug sevasemten fails a mid-stage trial. Ultragenyx cuts 20% of workforce and halts studies. ANI Pharmaceuticals offers to acquire Egetis Therapeutics for $560M.

Related tickers